Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSPIRE: Intensive Insulin in New Onset T2DM
NCT01087567Phase 4Completed
- Sponsor
- Ohio University
- Start
- Jul 2010
- Primary completion
- Jan 2014
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin glargine and insulin glulisine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Ohio University. Primary endpoints: Need for rescue therapy at 12 months and Change in A1C at 12 months. Started Jul 2010; status: completed.
02
Drugs
insulin glargineinsulin glulisine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01087567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01087567.